GlassScriptPhysician profile
Aditya Mandawat
NPI 1528351632
$3,365.59
in general payments reported to CMS, 2019-2025
22 companies · $389 in 2025
The $389 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $543 · 2021: $324 · 2022: $767 · 2023: $700 · 2024: $500 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,325.99 | 2021-2025 | Symplicity G3, Onyx Frontier, Telescope |
| Abiomed | $360.29 | 2020-2023 | Impella |
| Abbott Laboratories | $349.43 | 2020-2025 | Cardiomems, Xience Skypoint, Thoratec Heartmate 3 Lvas Implant Kit |
| Getinge USA Sales, LLC | $228.63 | 2019-2023 | Cardiohelp |
| Novartis Pharmaceuticals Corporation | $221.38 | 2020-2025 | |
| Medtronic Vascular, INC. | $168.16 | 2020 | |
| Cardiovascular Systems INC. | $128.74 | 2019-2021 | |
| Amgen INC. | $81.28 | 2020-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $73.30 | 2019-2025 | Watchman Flx, General - Atherectomy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $60.06 | 2019-2022 | |
| Asahi Intecc USA, INC. | $58.21 | 2020 | |
| Heartflow, INC. | $53.75 | 2024-2025 | |
| Biosense Webster, INC. | $50.26 | 2022-2024 | Carto 3 |
| Shockwave Medical, INC | $36.98 | 2020-2021 | |
| Pfizer INC. | $31.30 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $30.87 | 2025 | Orsiro Mission |
| Astrazeneca Pharmaceuticals LP | $23.81 | 2020 | |
| Novo Nordisk INC | $18.26 | 2023 | Ozempic |
| Sanofi-Aventis U.S. LLC | $17.33 | 2024 | |
| Philips North America LLC | $17.08 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.87 | 2024 | Xarelto |
| Cordis US Corp. | $14.61 | 2024 | Rain Sheath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aditya Mandawat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.